Derniers articles

Quality of Life and Needs in Caregivers: Results From the Prospective Multicentric Open-Label Randomized Study of Informal Caregivers of Elderly Patients

AbstractObjectives: To assess health-related quality of life (QoL) in caregivers of elderly patients with chronic...

Posté par : Mme. Aurélia MEURISSE
Nom de la revue : Int J Public Health

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)

AbstractBackground: Several cancer immunotherapies that target the PD-L1/PD-1 pathway show promising clinical...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study

AbstractPurpose: Baseline circulating tumour DNA (ctDNA) is a potential prognostic marker in metastatic colorectal...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

Prevalence and Characteristics of Sleep Apnea in Intensive Care Unit Survivors After SARS-CoV-2 Pneumonia

AbstractBackground: Sleep apnea (SA) was reported as possibly exacerbating symptoms of COVID-19, a disease induced...

Posté par : Mme. Aurélia MEURISSE, Dr. Sophie PAGET-BAILLY
Nom de la revue : Nature and Science of Sleep

Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial

AbstractSquamous Cell Carcinoma of the Anal canal (SCCA) is a rare disease associated with a Human Papillomavirus (HPV)...

Posté par : Mme. Aurélia MEURISSE
Nom de la revue : Front Oncol

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study

AbstractPurpose: Universal cancer peptide-based vaccine (UCPVax) is a therapeutic vaccine composed of two highly...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : J Clin Oncol

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T H 1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

AbstractBackground: There is a strong rational of using anti-programmed cell death protein-1 and its ligand...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Front Oncol

Early Post-Transplant Red Blood Cell Transfusion Is Associated With an Increased Risk of Transplant Failure: A Nationwide French Study

AbstractBackground: Red blood cell (RBC) transfusions are frequently required in the early period after kidney...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Frontiers in oncology

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer

AbstractBackground: There is a paucity of data regarding the prognostic influence of peripheral blood CD4+ T...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : BMC cancer

Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia

AbstractIntroduction: Survivors of viral ARDS are at risk of long-term physical, functional and neuropsychological...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Annals of Intensive Care

Is it safe to perform an anastomosis for rectal cancer after prostate cancer? A multicentre study of 126 patients from the GRECCAR group

AbstractAim: To determine the safety of performing an anastomosis after rectal cancer (RC) resection in patients...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Colorectal Dis

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

AbstractBackground: Squamous cell carcinoma of the anus (SCCA) is a rare disease often diagnosed at a localised...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study

AbstractHigh-risk HPV (hrHPV) testing has been implemented as a primary screening tool for cervical cancer in numerous...

Posté par : Mme. Julie HENRIQUES, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Cancers (Basel)

Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort

AbstractBackground: Metastatic signet-ring cell colorectal carcinoma is rare. We analyzed its clinicopathological...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Dig Liver Dis

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma

AbstractAims: The addition of docetaxel to cisplatin and 5-fluorouracil (DCF) has shown promising efficacy in...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Ther Adv Med Oncol

Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

AbstractFluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Int J Cancer

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

AbstractBackground: Immune checkpoint inhibitors (ICIs) are highly effective in patients with microsatellite...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : J Immunother Cancer

FOLFIRINOX De‐Escalation in Advanced Pancreatic Cancer: A Multicenter Real‐Life Study

AbstractBackground: Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5-fluorouracil...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Oncologist

Anti-Telomerase CD4 + Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials

AbstractDocetaxel, cisplatin and 5-fluorouracil (DCF) chemotherapy regimen is highly effective in advanced anal squamous...

Posté par : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Int J Mol Sci

Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group

AbstractBackground: Synchronous prostate cancer (PC) and rectal cancer (RC) is a rare clinical situation. While...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Ann Surg Oncol

Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE

AbstractBackground Metastatic Squamous cell Penile Carcinoma (mSCPC) is an orphan disease with a virally induced...

Posté par : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Bull Cancer

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative

AbstractBackground: The variability of definitions for time-to-event (TTE) end-points impacts the conclusions of...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE, Mme. Julie HENRIQUES
Nom de la revue : Eur J Cancer

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan

AbstractBackground: FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is an option for fit...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Clin Colorectal Cancer

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study.

AbstractIn patients with metastatic colorectal cancer (mCRC), RAS and BRAF mutations are currently determined by tumor...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Cancers

Morbidity and oncological outcomes of rectal cancer impaired by previous prostate malignancy.

AbstractBACKGROUND:Specific surgical and oncological outcomes in patients with rectal cancer surgery after a previous...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Br J Surg

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.

AbstractBACKGROUND:The benefit of second-line chemotherapy (L2) over standard first-line (L1) gemcitabine plus cisplatin...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Eur J Cancer.

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial

AbstractPurpose: Human papillomavirus (HPV) is found in 90% of squamous cell carcinomas of the anal canal (SCCA)....

Posté par : Mme. Aurélia MEURISSE
Nom de la revue : Clin Cancer Res .

Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study

AbstractAflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the...

Posté par : Mme. Aurélia MEURISSE, Pr. Franck BONNETAIN
Nom de la revue : Int J Oncol .

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.

ABSTRACTBACKGROUND:Two main therapies, pazopanib and sunitinib, are used in the first-line settingfor metastatic renal...

Posté par : , Mme. Joëlle FRITZSCH, Dr. Sophie PAGET-BAILLY, , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Health and Quality of Life Outcomes

Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)

AbstractBackground: 5-Fluorouracil (5-FU) and platinum-based perioperative chemotherapy is standard of care for...

Posté par : Mme. Aurélia MEURISSE
Nom de la revue : Eur J Cancer

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

AbstractBACKGROUND:The incidence of anal squamous cell carcinoma has been increasing markedly in the past few decades....

Posté par : Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

AbstractBACKGROUND:The incidence of anal squamous cell carcinoma has been increasing markedly in the past few decades....

Posté par : Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

ABSTRACTBackgroundSunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Trials

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

BACKGROUND:RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Nom de la revue : Ann Oncol

Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study

We conducted a retrospective study to assess the follow-up of patients with localized breast cancer and the first...

Posté par : Mme. Aurélia MEURISSE,
Nom de la revue : Breast

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for...

Posté par : , Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Nom de la revue : JNCI J Natl Cancer Inst

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial

Background Nab-paclitaxel plus gemcitabine has become a standard treatment regimen in patients with metastatic...

Posté par : Mme. Aurélia MEURISSE, Pr. Franck BONNETAIN
Nom de la revue : Lancet Gastroenterology Hepatology

 Archives

 Contributor